CASES FOR DISCUSSION. Yohannes B

Similar documents
WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Learning Objectives. After attending this presentation, participants will be able to:

Chronic Hepatitis B Infection

Pretreatment Evaluation

Module 1 Introduction of hepatitis

Hepatitis and pregnancy

Pretreatment Evaluation

Toronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action

Pretreatment Evaluation

Updates in the Treatment of Hepatitis C

World Health Organization. Western Pacific Region

Hepatitis C Update on New Treatments

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases

EAST LONDON INTEGRATED CARE

Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1

Patterns of abnormal LFTs and their differential diagnosis

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Emerging Challenges In Primary Care: 2015

Emerging Challenges In Primary Care: Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How

Emerging Challenges In Primary Care: 2015

Treatment of chronic hepatitis delta Case report

World Health Organization. Western Pacific Region

Hepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?

ACTIVITY DISCLAIMER. Kurt Cook, MD, MSc DISCLOSURE. Audience Engagement System. Learning Objectives

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

Viral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH

SEVERE LIVER DISEASES & HIV INFECTION

Patterns of abnormal LFTs and their differential diagnosis

Cases: Treatment of Hepatitis C in Patients with Cirrhosis and Advanced Liver Disease

Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018

Hepatitis C in Disclosures

Clinical dilemmas in HBeAg-negative CHB

Non-Invasive Testing for Liver Fibrosis

HCV Case Studies (and Special Populations)

Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus / Fax

HCV care after cure. This program is supported by educational grants from

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

HBV in HIV Forgotten but not Gone

Meet the Professor: HIV/HCV Coinfection

in pregnancy Document Review History Version Review Date Reviewed By Approved By

Hepatology cases for the generalist. Will Gelson Consultant Hepatologist Addenbrooke s Hospital

Viral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP

Update on Hepatitis B and Hepatitis C

Hepatitis C Policy Discussion

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Approach to Abnormal Liver Tests

Should we treat hepatitis B positive pregnant women to prevent mother to child transmission?

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Hepatology For The Nonhepatologist

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

Blood-Borne Viruses and Pregnancy. Prof Ashley Brown Imperial Healthcare NHS Trust

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Approved regimens for cirrhotic patients

Physical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Treatment of hepatitis B : the guidelines and real life

ABCs of Viral Hepatitis What Primary Care Physicians Need to Know

Position Paper of the Italian Association for the Study of the Liver for the rational use of anti-hcv drugs available in Italy

HEPATITIS B: WHO AND WHEN TO TREAT?

Management of Hepatitis B - Information for primary care providers

The Hep B Moms Program: A Primary Care Model for Management of Hepatitis B in Pregnancy

Treatment of HCV in the Era of DAAs in Pakistan

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a

MA PERINATAL HEPATITIS B PREVENTION PROGRAM

Global reporting system for hepatitis (GRSH) project description

Outline. HCV Disease Outcomes in the US. Hepatitis C: The New Landscape 5/24/16. Advances in Internal Medicine May 24, I have no disclosures

World Health Organization. Western Pacific Region

HCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016

DILEMMAS IN THE MANAGEMENT OF CO-INFECTION IN HIV-INFECTED CHILDREN

The Long Term Care Risk

4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives

Hepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST

Liver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients

Hepatitis C Policy Discussion

The Impact of HBV Therapy on Fibrosis and Cirrhosis

Management of Hepatitis B

Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Management of Chronic Hepatitis B in Asian Americans

S401- Updates in the Treatments of Hepatitis B & C

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm

Viral Hepatitis Update: Screening, Vaccination, and Treatment

Liver and pregnancy part 2 : pregnancy in patient with underlying liver disease

Viral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician

Case 2: A 71-year-old man with cirrhosis

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Emerging Challenges In Primary Care: 2015

HPI (2006) Question: Douglas T. Dieterich, MD. What is the risk of mother-to-child transmission in HCV for this woman?

Management of Hepatitis C

CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS

Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV)

Transcription:

CASES FOR DISCUSSION Yohannes B

HCV

CASE-1 A 34 years old apparently healthy lady who came to us after being told to have HCV infection on medical checkup done as part of a visa approval process to travel to the one of the middle east countries. P/E showed normal findings CBC, liver enzymes, LFT and abdominal u/s was also found to be normal

CASE 2 A 50 yrs old man came to our clinic with a complaint of fatigue since 2 years, progressive abdominal distension of 3 months duration with associated poor appetite and un-qualtified but significant wt loss P/e- chronically sick, with stable V/S, icteric sclerae, muscle wasting and +v signs of fluid collection in the peritoneum.

Lab data WBC- 4000 Hgb -9.6, MCV- 79 plt- 92,000 RFT and Elec =WNL, AST- 210, ALT 160, ALP-150, INR-1.7, bil-t-2.9 D-1.6 Anti HCV Ab -+ve, HBsAg and HIV serology were ve. U/S revealed Nl sized liver with with blunted edge, irregular surface and heterogeneous echotexture with ascites and splenomegaly.

CASE 3 A 28 yrs old lady who just started ANC followup for 1 st TM pregnancy was told to have HCV on workup and her obstetrician sent her to us for possible evaluation of the viral hepatitis p/e was unremarkable Lab workup including CBC, LFT, Liver enzymes, HBsAg, and HIV screening were NL. And u/s showed normal abdominal scan with no signs of cirrhosis

Who to treat.?

Prioritization for Evidences for cirrhosis Showing worsening of liver dis. Severe extra hepatic manifestations Hiv/Hbv co infection Other causes of liver disease High risk for transmission groups

1. Incidental HCV ab positive pt what is the way forward:

-confirm Dx -prioritize based on : -assessment of degree of fibrosis ( how? ) -presence of other co morbidities ( HIV /HBV) -other causes of liver disease -extra hepatic manifestations -worsening liver disease

Assesment of liver fibrosis -liver biopsy ( not much practical ) -non invasive ways like -APRI = (AST elevation/platelet count) x 100 -A meta-analysis of 40 studies provided the following estimates : -An APRI threshold of 0.7 had an estimated sensitivity and specificity of 77 and 72 percent for significant fibrosis. -An APRI threshold of 1.0 had an estimated sensitivity and specificity of 76 and 72 percent for cirrhosis.

-FIB-4 -Formula : -( Age x AST ) / ( Platelts x ( sqr ( ALT ) ) -For HCV with or without HIV : -Fib4 score < 1.45 = F0-F1 -Fib4 score > 3.25 = F3-F4

-FIBROSCAN ( U/S transient elastography ) -In two meta-analyses, the pooled estimates for the diagnosis of cirrhosis with TE were excellent, with sensitivity and specificity values approaching 90%. -Reported diagnostic threshold (or cutoff ) values for cirrhosis have ranged between 11 and 17 kpa in studies of patients with chronic hepatitis C.

2.pt with cirrhosis who turns out to have hcv infection-

-confirm the Dx ( quantitative HCV RNA ) -already in the priority group so proceed to genotype testing and pre-treatment evaluation -initiate therapy * The APRI (200/40)/96 X 100= 5.2

3.pregnant lady hcv +ve during screening

- concern is MTCT and health of the mother - assess the mother as for case 1 - low vertical transmission rate of 3 5% - Factors known to increase the risk of perinatal transmission- HIV coinfection and higher maternal viral loads

- No active preventive strategy ( vaccines or drug therapy ) - Vaginal delivery vs c/s controversial ( recent evidences from Italy and china showing benefit of c/s in high risk groups ) - breast feeding is safe

CHALLENGES Screening most pts come with advanced liver disease Cost of investigations Cost and availability of medications Lack of knowledge

What is available.. - SOF/LDV - SOF - RBV

HBV

CASE 1 40 years old male from Gondar Found to be +ve for HBsAg on routine check up p/e unremarkable except for being marginally overweight and having a BP of 140/90 Lab data including LFT, CBC, Liver enzymes, RFT, HCV Ab are all NL. U/S Normal findings

CASE 2 A 38 years old male pt from Nazret who presented to our ER 3 days back with 2 days history of hematemesis and melena Further enquiry revealed that pt has been having long standing fatigue, and progressive abdominal distension with associated poor appetite and bilateral leg swelling since 5 months. He has had a similar episode of UGI bleeding 3 months back he received blood transfusion and was told to have a liver disease and was put on diuretics at that time.

On presentation pt was hypotensive with a BP of 80/ 50 PR= 120, temp- 36.7 -severe pallor, icteric -ascites, visible abdominal wall collaterls -bilateral pedal edema -conscious and oriented

Lab data hgb =4.6 plt 68000 WBC= 6000 -Crt-1.4, BUN=80 -ALB= 2.5, INR- 1.5 -AST= 134 and ALT -62 -Bil-T-3.4 D- 2.1 Bedside U/S Cirrhotic liver with splenomegaly and massive ascites

Transfusion PRBC and FFP Prophylactic ABC Endoscopy actively bleeding grade 3 esophageal varices + severe PHG EBL done

CASE 3 A 34 yrs old gravida 3 woman in her 1 st TM who is sent to you from ANC clinic for evaluation of a + HBsAg test. p/e normal findings Lab data CBC, RFT, Elec. = Nl AST and ALT Nl ALP slightly raise bil, alb, INR and abd Abd u/s Normal.

INDICATION FOR TREATMENT Decision to treat HBV is based on -Elevated ALT -HBV DNA (viral load) -Severity of liver disease( degree of fibrosis ) -HBeAg status -Age -Comorbidities

Who to treat: WHO 2015 30

Who to treat WHO 2015 31

32

1. A pt found to have +Ve HBsAg with normal liver enzymes, LFT and imaging studies. - 1 st confirm chronicity of infection - follow up HBsAg after 6 months or antihbcab - assess degree of fibrosis ( Bx Vs noninvasive measures ) - can follow pt with LFT and clinically Q 6-12 mo - but if there is evidence of significant fibrosis or persistent elevation of transaminases, determine viral load and consider treatment Q- How far should we go in investigating such patients?

2. pt with cirrhosis and +Ve HBsAg test - indication for therapy so do pretraetment evaluation and start treatment -treat complications -Surveilance for HCC

3. pregnant woman found to be HBsAg +Ve on screening -Do HBV viral load and HBeAg -antiviral therapy if viral load is > 1 mill copies and HBeAg +V or if the mother has an indication for therapy -HBV vaccine and HBIG for the new born baby ( esp if HBeAg +ve ) * -in resource limited setting and in those with HBeAg v, HBV vaccine may suffice.

THANK YOU